NCT06930729 Optimizing Care for Cancer Survivors With Depression: Project 3
| NCT ID | NCT06930729 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of South Carolina |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2025-08-12 |
| Primary Completion | 2026-09-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2025-08-12 with a primary completion date of 2026-09-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to evaluate different depression treatment approaches among cancer survivors. A cancer survivor is defined as anyone who is living and has been diagnosed with cancer. Participants will be randomly assigned to either receive a mobile app for depression treatment, called "Moodivate", or to receive telehealth depression treatment sessions. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will receive depression treatment via telehealth. Participants that receive Moodivate may later be assigned to also receive depression treatment via telehealth based their response to the Moodivate app. Participants will be asked to either use the Moodivate app and/or receive depression treatment via telehealth for a period of 10 weeks. All participants will be asked to electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as general experiences using Moodivate and participating in this trial. Participation in this study will take about 24 weeks. Participation in this study may help improve options for emotional wellness for cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality.
Eligibility Criteria
Inclusion Criteria: * age 18+ * cancer survivor * current elevated depressive symptoms defined per ASCO as a PHQ-9 score ≥ 8 * not currently receiving psychosocial depression treatment * have the ability to complete treatment via telehealth and use Moodivate * have a valid e-mail address or text message access (for assessments) * English fluency Exclusion Criteria: \- Current suicidal ideation at final eligibility screening (PHQ-9 item 9 ≥1)
Contact & Investigator
Jennifer Dahne, MD
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT06930729 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06930729 currently recruiting?
Yes, NCT06930729 is actively recruiting participants. Contact the research team at levins@musc.edu for enrollment information.
Where is the NCT06930729 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT06930729 clinical trial?
NCT06930729 is sponsored by Medical University of South Carolina. The principal investigator is Jennifer Dahne, MD at Medical University of South Carolina. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.